Sunlenca (Lenacapavir Sodium) Patent Expiration, LOE Window & CMS Spending
Sunlenca (Lenacapavir Sodium) by Gilead Sciences: FDA Orange Book core substance LOE 2038-08-16 (last listed 2041-08-28), 0 AB generics, $29.1M 2024 CMS Part D & Medicaid spend, and $19,500 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Gilead Sciences |
| FDA Application & Pathway | N215973 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2038-08-16 |
| Last Listed Patent or Exclusivity Date | 2041-08-28 |
| Orange Book Patents (*PED Extensions) | 6 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $29.1M |
| 2024 Medicare Part D Spend | $18.3M |
| 2024 Medicaid Spend | $10.8M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($19,500 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.